



Mahzi Therapeutics

Ad ·



■ 30 million Americans live with rare diseases. Less than 10% of those diseases have an FDA-approved therapy.

Mahzi Therapeutics is developing precision therapies for devastating neurogenetic disorders linked to autism, seizures, and developmental delays.

Backed by leading VCs and supported by \$16M from the California Institute for Regenerative Medicine.

👉 The first two subjects have now been dosed in the first-ever gene therapy trial for Pitt Hopkins syndrome.

Join the movement. Invest in the future of rare disease medicine.

Disclaimer:

We are 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. See here for important legal disclosures: help.wefunder.com/testing-the-waters-legal-disclosure



"For families who have waited years for meaningful therapeutic progress, this moment reflects countless hours of advocacy, collaboration, and perseverance."

— Audrey Davidson, President of the Pitt Hopkins Research Foundation



MAHZI
THERAPEUTICS

INVEST ON
WEFUNDER

wefunder.com

Mahzi Therapeutics

Advancing precision ther...

See details



Like



Comment



Share